Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin in HER2-positive gallbladder or biliary tract cancer
NCT00478140Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2007
- Primary completion
- Nov 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in gallbladder cancer, biliary tract cancer (BTC), sponsored by National Cancer Institute. Started May 2007; status: terminated.
02
Drugs
03
Conditions
gallbladder cancerbiliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT00478140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478140.